https://bms309403inhibitor.com..../trajectories-regard
Amount of evidence Prognostic Level III. See Instructions for Authors for a whole information of quantities of evidence.Goals To describe the occurrence of malabsorption (MA) in hepatocellular carcinoma (HCC) patients under sorafenib, the potential relationship with pancreatic insufficiency (PI), in addition to role of pancreatic enzymes supplementation. Background because of the increasing options of second-line systemic therapies for HCC, the recognition of medici
Like
Comment
Share
